Abstract:Rongce Zhao, 1, &ast Jing Zhou, 2, &ast Zehao Zheng, 1, &ast Xinhao Xiong, 1 Qiaoxuan Wang, 3 Shaohua Li, 1 Wei Wei, 1 Rongping Guo 1 1 Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 2 Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 3 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Rongping Guo; Wei Wei, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China, Email ; Background: For patients with large unresectable hepatocellular carcinoma (HCC), the effectiveness of conventional transarterial chemoembolization (TACE) remains suboptimal, which necessitates the administration of substantial volumes of chemotherapy drugs and lipiodol, thereby increasing the risk of liver failure and other chemotherapy-related complications. Therefore, we devised a strategy of initial hepatic arterial infusion chemotherapy (HAIC) followed by sequential drug-eluting bead TACE (DEB-TACE). In our treatment design, a lower tumor burden after HAIC facilitated complete embolization of tumor vasculature, and the use of less amount of embolic agents reduced the incidence of liver failure and embolization syndromes. Methods: This retrospective study evaluated consecutive patients with unresectable large HCC with a maximum tumor diameter of ≥ 7 cm who received FOLFOX-HAIC combined with sequential DEB-TACE from April 2019 to February 2024. Efficacy was evaluated using the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS); and safety was assessed using the frequency of key adverse events (AEs). Results: Among the 76 patients included, the median maximum tumor diameter was 12.4 cm (range, 7.0– 23.4 cm). The overall ORRs based on mRECIST and RECIST 1.1 criteria were 94.1% and 51.5%, respectively. The median OS was 28.1 months (95% CI, 22.7– 33.4), and the median PFS was 11.7 months (95% CI, 7.7– 15.8). All patients experienced AEs, but only 18.4% experienced grade 3 or 4 AEs, there was no treatment-related mortality. Conclusion: In this single-center, retrospective study, our results suggested that FOLFOX-HAIC with sequential DEB-TACE demonstrated promising efficacy and safety for patients with unresectable HCC with a maximum tumor diameter of ≥ 7 cm. Keywords: large unresectable hepatocellular carcinoma, hepatic arterial infusion chemotherapy, drug-eluting bead transarterial chemoembolization, sequential Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and is the third leading cause of cancer-related deaths worldwide. 1 Approximately 80% of HCC cases worldwide are in developing countries, 2,3 where HCC surveillance is not widely applied. Consequently, most patients in these areas with the highest risk of HCC are initially diagnosed with large tumors. 4 However, most large HCC cases are not suitable candidates for surgical resection because of insufficient residual liver volume, insufficient surgical margins, or macrovascular invasion. 5 The Barcelona Clinic Liver Cancer (BCLC) guidelines advocate the use of transarterial chemoembolization (TACE) as a therapeutic strategy for patients with unresectable HCC. 6 However, the effectiveness of TACE is often suboptimal in patients with large HCC tumors, 7,8 which have abundant extrahepatic collateral arteries, making it difficult to perform complete embolization. In addition, the use of a large amount of embolization agents may cause serious adverse events (SAEs), such as hepatic dysfunction, postembolization syndrome, and ectopic embolization. 9,10 Hepatic arterial infusion chemotherapy (HAIC) exerts its antitumor effect through the continuous infusion of high concentrations of chemotherapeutic agents. 11 In recent years, several studies have demonstrated that HAIC with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) significantly improved the survival of patients with advanced HCC. 12–14 Li et al report -Abstract Truncated-

Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma

Drug-eluting Bead Transarterial Chemoembolization (TACE) Exhibits Superior Efficacy and Equal Tolerance to Conventional TACE in Hepatocellular Carcinoma Patients with Conventional TACE History

The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma

719P Tyrosine Kinase Inhibitors And/or Immune Checkpoint Inhibitors is Required for Improving Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Large-Scale Multicenter Real-World Study of 582 Patients

Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma

Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus

FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC

Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma.

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study

Efficacy and Safety Assessment of Drug-Eluting Bead Transarterial Chemoembolization Combined with Molecular Targeted Agents or Immunotherapy in Unresectable Hepatocellullar Carcinoma: Real-world Evaluation.

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma

A Retrospective Study Exploring the Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy and Sequential Transarterial Embolization Combined with Lenvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?

The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.